Reversing Heparin in a Patient Sensitized by Years of NPH Insulin
A 66-year-old man with twenty years of NPH insulin exposure needs his heparin reversed at the end of bypass. The only reversal agent available carries a real reaction risk in exactly his history — and the argument over how to give it turns on a distinction the team can't actually confirm until it's already happening.
Samuel P., a 66-year-old man, has managed type 1 diabetes since a diagnosis at 19, and for most of those forty-seven years his regimen included NPH insulin twice daily — only in the last five years did his endocrinologist transition him toward a newer basal-bolus analog regimen. That arithmetic is the entire risk factor: roughly forty-two years of daily subcutaneous exposure to protamine itself, since NPH is formulated with protamine to extend its duration of action. He arrives today for triple-vessel CABG after an NSTEMI found severe disease not amenable to further stenting, well controlled on his current regimen with an A1c of 6.9%, and with no history of prior cardiac surgery or protamine exposure in any surgical context — meaning the sensitization risk in front of the team arrived entirely through his insulin, never through an operating room.
Repeated protamine exposure, even through a subcutaneous insulin formulation rather than an intravenous bolus, is a recognized route of sensitization, and patients with this history carry meaningfully elevated risk of a reaction when protamine is later given IV to reverse heparin at the end of bypass. He is stable on bypass now, MAP 68 with no vasopressor requirement, which is the one piece of good news available: whatever happens when the protamine goes in will happen to a patient who is not already compensating for something else. What his history cannot tell the team is which kind of reaction he might be primed for — a true IgE-mediated response, against which slow administration offers little protection, or the more common complement-mediated anaphylactoid reaction, which genuinely does respond to a slower rate of exposure. Forty-two years of antigen exposure is precisely the history capable of producing either one, and nothing in his chart discriminates between them; that uncertainty, rather than the size of the risk, is what the room is working through before his bypass run even ends.
Before the first milliliter of protamine
I want a slow titration — test dose, then infuse the remainder over fifteen to twenty minutes with the whole team watching his hemodynamics, not a rapid bolus. Complement-mediated anaphylactoid reactions are the more common protamine reaction and they're genuinely rate-dependent; slowing the exposure reduces the speed and magnitude of mast cell degranulation.
I'd push back on that as the default here. If his reaction risk is instead IgE-mediated — and forty-two years of chronic antigen exposure is exactly the kind of history that can produce true sensitization, not just the complement pathway — slowing the rate doesn't meaningfully protect him. A truly sensitized patient can react to a small initial exposure regardless of how slowly the rest is given.
And a prolonged titration isn't free — every extra minute he spends with heparin only partially reversed is a minute of ongoing anticoagulated bleeding at a fresh triple-vessel graft field. If the slow approach only protects against one of two plausible mechanisms, I don't think it clearly wins on balance.
That's a fair distinction and I don't have a way to know in advance which mechanism applies to him — you're right that I can't promise the slow approach covers his actual risk. I'll take the middle ground: a real test dose first, watched closely for a couple of minutes, and if there's no early reaction, the remainder given faster than a full twenty-minute titration but still not a single rapid bolus.
That gets us most of the protection against the more common reaction type without extending his anticoagulated field time as long as a full slow protocol would. Diphenhydramine on board beforehand either way, and the resuscitation cart already open in the room.
Agreed: test dose given first, watched for two minutes with no early hemodynamic change, then the remainder given over roughly eight minutes rather than a full twenty-minute protocol or a rapid bolus. No reaction occurred; heparin reversal confirmed adequate by repeat ACT.
Not agreed as a general principle: whether the compromise protocol adopted here should become the standard approach for future NPH-exposed patients, or whether it represents a genuine middle ground that undersells the protection a full titration offers while oversaving the time a full bolus would. Both voices accepted it as reasonable for today without either fully endorsing it as the new default.